BACKGROUND: ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome. METHODS: A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher's exact test and Mehta's modification to Fisher's exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome. RESULTS: We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051). CONCLUSIONS: Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.
BACKGROUND:ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome. METHODS: A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher's exact test and Mehta's modification to Fisher's exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome. RESULTS: We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051). CONCLUSIONS: Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.
Authors: Hani B Marcos; Steven K Libutti; H Richard Alexander; Irina A Lubensky; David L Bartlett; McClellan M Walther; W Marston Linehan; Gladys M Glenn; Peter L Choyke Journal: Radiology Date: 2002-12 Impact factor: 11.105
Authors: Brian M Wolpin; Peter Kraft; Mousheng Xu; Emily Steplowski; Martin L Olsson; Alan A Arslan; H Bas Bueno-de-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Naomi E Allen; Laufey Amundadottir; Melissa A Austin; Marie-Christine Boutron-Ruault; Julie E Buring; Federico Canzian; Stephen J Chanock; J Michael Gaziano; Edward L Giovannucci; Göran Hallmans; Susan E Hankinson; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Charles Kooperberg; Julie B Mendelsohn; Dominique S Michaud; Kim Overvad; Alpa V Patel; Maria-José Sanchéz; Leah Sansbury; Xiao-Ou Shu; Nadia Slimani; Geoffrey S Tobias; Dimitrios Trichopoulos; Paolo Vineis; Kala Visvanathan; Jarmo Virtamo; Jean Wactawski-Wende; Joanne Watters; Kai Yu; Anne Zeleniuch-Jacquotte; Patricia Hartge; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-22 Impact factor: 4.254
Authors: Simona Iodice; Patrick Maisonneuve; Edoardo Botteri; Maria Teresa Sandri; Albert B Lowenfels Journal: Eur J Cancer Date: 2010-12 Impact factor: 9.162
Authors: T Nakagoe; A Nanashima; T Sawai; T Tuji; M Ohbatake; M Jibiki; H Yamaguchi; T Yasutake; H Ayabe; T Matuo; Y Tagawa Journal: J Cancer Res Clin Oncol Date: 2000-07 Impact factor: 4.553
Authors: H Matsumoto; H Muramatsu; T Shimotakahara; M Yanagi; H Nishijima; N Mitani; K Baba; T Muramatsu; H Shimazu Journal: Cancer Date: 1993-07-01 Impact factor: 6.860
Authors: David Melzer; John R B Perry; Dena Hernandez; Anna-Maria Corsi; Kara Stevens; Ian Rafferty; Fulvio Lauretani; Anna Murray; J Raphael Gibbs; Giuseppe Paolisso; Sajjad Rafiq; Javier Simon-Sanchez; Hana Lango; Sonja Scholz; Michael N Weedon; Sampath Arepalli; Neil Rice; Nicole Washecka; Alison Hurst; Angela Britton; William Henley; Joyce van de Leemput; Rongling Li; Anne B Newman; Greg Tranah; Tamara Harris; Vijay Panicker; Colin Dayan; Amanda Bennett; Mark I McCarthy; Aimo Ruokonen; Marjo-Riitta Jarvelin; Jack Guralnik; Stefania Bandinelli; Timothy M Frayling; Andrew Singleton; Luigi Ferrucci Journal: PLoS Genet Date: 2008-05-09 Impact factor: 5.917
Authors: R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano Journal: J Endocrinol Invest Date: 2022-08-30 Impact factor: 5.467
Authors: Allison B Weisbrod; Naris Nilubol; Lee S Weinstein; William F Simonds; Steven K Libutti; Robert T Jensen; Stephen J Marx; Electron Kebebew Journal: J Clin Endocrinol Metab Date: 2012-10-23 Impact factor: 5.958
Authors: Xavier M Keutgen; Pascal Hammel; Peter L Choyke; Steven K Libutti; Eric Jonasch; Electron Kebebew Journal: Nat Rev Clin Oncol Date: 2016-03-31 Impact factor: 66.675